Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A phase 1 trial of sofetabart mipitecan plus bevacizumab delivered a nearly 80% overall response rate in women with platinum-sensitive ovarian cancer — far outpacing current standard-of-care options. Even patients previously treated with PARP inhibitors responded at nearly 79%. Median progression-free survival hadn't been reached after 10 months of follow-up, signaling potentially durable benefit.
For women with recurrent platinum-sensitive ovarian cancer, treatment options are limited and increasingly ineffective — fewer than half respond to therapies after prior PARP inhibitor treatment. But a new phase 1 trial presented at the European Society for Medical Oncology (ESMO) Congress is turning heads with some striking early results.
The combination of sofetabart mipitecan — a folate receptor alpha-targeting antibody drug conjugate from Eli Lilly — and bevacizumab achieved a confirmed overall response rate of 79.3% in 33 patients, with a 100% disease control rate. Crucially, the median duration of response and progression-free survival (PFS) had not yet been reached at follow-up, suggesting the benefits may be long-lasting.
By the Numbers:
Why it matters: Current therapies for this patient population are largely retreads of platinum-based chemo with diminishing returns. Sofetabart mipitecan's robust responses — especially in PARP inhibitor-pretreated patients — represent a meaningful step forward. A phase 3 trial (FRAmework-01) comparing this combo against platinum-based chemotherapy is now underway.
